Abstract
Solid tumours present numerous obstacles for efficient systemic delivery of therapeutic agents. This goal has to face specific problems related to the nature of each targeting element, but also the physical barriers posed by tumours, such as heterogeneous blood supply and elevated interstitial pressure. These barriers impair the delivery to tumours of antibodies or viral particles. Immune cells are supposed to be endowed with the ability to target tumours, but in general, tumour cells themselves provide poor targets for immunological responses. A key challenge of tumour gene therapy (cell carrier- and / or viral vector-mediated) is to control the site at which genes are expressed by instructing cells or virus or to distinguish between target and non-target tissue. Thus, antibody-directed targeting of virus or cells could potentially improve both the safety and the efficacy of therapeutic gene delivery to tumours. Furthermore, virus production can rely on carrier cells under the transcriptional control of a factor activated after specific triggering of a tumour-specific receptor. Given that any of these anti-tumour strategies by themselves have fulfilled their therapeutic potential, we propose here their combination for developing more effective anti-cancer therapies.
Keywords: cancer, gene therapy, antibody engineering, virus targeting
Current Gene Therapy
Title: Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Volume: 5 Issue: 1
Author(s): Laura Sanz, Jian Qiao, Richard G. Vile and Luis Álvarez-Vallina
Affiliation:
Keywords: cancer, gene therapy, antibody engineering, virus targeting
Abstract: Solid tumours present numerous obstacles for efficient systemic delivery of therapeutic agents. This goal has to face specific problems related to the nature of each targeting element, but also the physical barriers posed by tumours, such as heterogeneous blood supply and elevated interstitial pressure. These barriers impair the delivery to tumours of antibodies or viral particles. Immune cells are supposed to be endowed with the ability to target tumours, but in general, tumour cells themselves provide poor targets for immunological responses. A key challenge of tumour gene therapy (cell carrier- and / or viral vector-mediated) is to control the site at which genes are expressed by instructing cells or virus or to distinguish between target and non-target tissue. Thus, antibody-directed targeting of virus or cells could potentially improve both the safety and the efficacy of therapeutic gene delivery to tumours. Furthermore, virus production can rely on carrier cells under the transcriptional control of a factor activated after specific triggering of a tumour-specific receptor. Given that any of these anti-tumour strategies by themselves have fulfilled their therapeutic potential, we propose here their combination for developing more effective anti-cancer therapies.
Export Options
About this article
Cite this article as:
Sanz Laura, Qiao Jian, Vile G. Richard and Álvarez-Vallina Luis, Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?, Current Gene Therapy 2005; 5 (1) . https://dx.doi.org/10.2174/1566523052997479
DOI https://dx.doi.org/10.2174/1566523052997479 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Graphical Abstracts:
Central Nervous System Agents in Medicinal Chemistry Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry Salvage Hypofractionated Radiotherapy in Combination with Bevacizumab in Patients with Recurrent High Grade Glioma: A Mono-institutional Experience
Clinical Cancer Drugs Meet Our Associate Editor
Current Molecular Medicine Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery Photo- and Sono-Dynamic Therapy: A Review of Mechanisms and Considerations for Pharmacological Agents Used in Therapy Incorporating Light and Sound
Current Pharmaceutical Design Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Glioblastoma Therapy – Part I (Guest Editor: Hui-Wen Lo)]
Anti-Cancer Agents in Medicinal Chemistry